Scroll To Top
Search by Speciality

2017 NEUROSCIENCE EDUCATION INSTITUTE (NEI) CONGRESS

Broadmoor Convention Center | Colorado springs, USA
From 99 to 899 USD
Event Preview
EXPIRED
This event
is Finished
Title: 2017 NEUROSCIENCE EDUCATION INSTITUTE (NEI) CONGRESS
Specialty: Clinical Pharmacology
Dates: From Nov, 8, 2017 to Nov, 12, 2017
Location: Colorado springs, USA
Type: Congress
Registration Cost: From 99 to 899 USD
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
Nov
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for COLORADO SPRINGS, Usa.
General Info
Event Venue:

Broadmoor Convention Center

COLORADO SPRINGS, USA Visit the Venue to read more
Currency:
USD
Accreditation:

-

Accreditation with Commendation


NEINEI is recognized as a leader in quality education, having again received ACCME Accreditation with Commendation, through 2019.

Accreditation and Credit Designation Statements


NEIThe Neuroscience Education Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 


The Neuroscience Education Institute has approved this live activity for 24.0 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

asapThe American Society for the Advancement of Pharmacotherapy (ASAP), Division 55 of the American Psychological Association, is approved by the American Psychological Association to sponsor continuing education for psychologists. ASAP maintains responsibility for this program and its content. 


The American Society for the Advancement of Pharmacotherapy designates this program for 24.0 CE credits for psychologists.

Nurses and Physician Assistants: for all of your CE requirements for recertification, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content of this activity pertains to pharmacology and is worth continuing education hours of pharmacotherapeutics.

Concerned Audience:
  • Medical_Professionals
  • Medical_students
  • Nurses
Event Overview
Welcome message:

Attend the NEI Congress to hear the most influential leaders in the field of psychiatry discuss the best practices for identifying and managing patients with mental illnesses. From the optimal use of available treatments and diagnostic techniques to the relevance of novel tools, this symposium will guide your ability to provide effective treatment and management of your most difficult cases.


What will you gain?

Gain valuable education on differential diagnostic considerations and effective clinical strategies for patients who don’t respond to first-line treatment. Each session will provide you with key takeaways that are applicable for “real world” clinical decisions, helping you improve patient outcomes.


How will the latest breakthroughs impact your practice?

Learn about the recent advances in neuroscience and diagnostic and treatment strategies that may impact your clinical practice. Clarify your concerns, review the scientific data, and learn how to prepare your practice for these changes.

For cutting-edge education, networking and fun, attend the NEI Congress!

Earn up to 30 CME credits (Congress plus two workshops)

Meet poster presenters and discuss their research data, clinical trial data, or clinical cases

Extend your knowledge during Industry Symposia—no additional cost

Discover the latest products and services at the Exhibit Hall

Target Audience

This content has been developed for prescribers specializing in psychiatry. All other health care providers interested in psychopharmacology are welcome for advanced study, especially primary care physicians, nurse practitioners, psychologists, and pharmacists.

Speakers/Faculty:

Andrew J. Cutler, MD

Executive Vice President and Chief Medical Officer, Meridien Research, Tampa, FL 


Dr. Andrew J. Cutler is EVP and Chief Medical Officer of Meridien Research Group in Tampa, FL. Dr Cutler received his medical degree from the University of Virginia School of Medicine and continued his medical training at the University of Virginia Medical Center where he served as an intern, resident, and chief resident in Psychiatry and Internal Medicine. While at the University of Virginia, he also completed training in dopamine receptor pharmacology and clinical psychopharmacology research. He then served as a Legislative Fellow and Mental Health Advisor to US Senator Paul Wellstone in the 103rd U.S Congress.


He has devoted more than 20 years to clinical research, and he has been principal investigator on more than 400 psychiatric and medical clinical trials. He has also published more than 60 peer-reviewed articles, presented over 100 abstracts at national and international medical meetings, and he has given hundreds of invited CME and promotional talks around the world. 


He regularly speaks to professional and community audiences about the evaluation and treatment of mental illnesses such as ADHD, anxiety disorders, bipolar disorder, depression, and schizophrenia. He has received several professional honors and awards, including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Effective Legislative Fellow Award from the National Alliance for the Mentally Ill, the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida, and he was chosen by his peers as the best psychiatrist in Orlando 5 years in a row (2003-2007).


Dr. Cutler is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine, and holds the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research.


 neiIra D. Glick, MD

Professor Emeritus, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 

Adjunct Professor, Department of Psychiatry, New York University School of Medicine, New York, NY


Dr. Ira D. Glick joined the faculty of the Stanford University School of Medicine in July, 1993. He has been Professor of Psychiatry at the University of California, San Francisco (UCSF) from 1968 to 1978 and at the Cornell University Medical College from 1978 – 1993. During his tenure at Cornell, he was also Senior Science Advisor to the Director of the National Institute of Mental Health (from 1988 – 1990). Dr. Glick’s research has focused on 1) the effectiveness of psychiatric hospitalization, 2) the current and future treatment of schizophrenia and mood disorders including combining medication and psychotherapy (both individual as well as family therapy) and 3) the diagnosis and treatment of athletes (Sports Psychiatry).


A 1961 graduate of New York Medical College, Dr. Glick is a 1) Distinguished Fellow of the American Psychiatric Association and founding member of both the American Family Therapy Academy and the International Society of Sports Psychiatry (ISSP) and a member of the Board of Directors of the American Society of Clinical Psychopharmacology (ASCP). Dr. Glick has been elected to membership of the American College of Neuropsychopharmacology (ACNP) and the American College of Psychiatrists. He has authored or co-authored more than 200 scientific articles and book chapters, eight books as well as psychopharmacology curriculums for teachers of 1) psychiatric residents, 2) for medical students and 3) for primary care physicians.


He has received numerous awards for his research and teaching including those from the American Psychiatric Association, American College of Neuropsychopharmacology and the Association of Academic Psychiatry – plus the 2014 K P Soo Award from the Am Psychiatric Association - as well as an “exemplary psychiatrist” from the National Alliance for Mental Illnesses (NAMI). In 2017 he received the Dean Award from the American College of Psychiatrists for his research in Schizophrenia. He was appointed Emeritus Professor at Stanford in 2010. He is now (2017) Visiting Professor at three medical schools—Weill Cornell Medical College, NYU, and UC San Diego—and has recently rejoined the faculty at UC San Francisco.


 neiDavid W. Goodman, MD, FAPA

Director, Adult Attention Deficit Disorder Center of Maryland, Baltimore, MD 

Director, Suburban Psychiatric Associates, LLC, Baltimore, MD 

Assistant Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD


Dr. David W. Goodman is Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. He is also Director of the Adult Attention Deficit Disorder Center of Maryland in Lutherville and Director of Suburban Psychiatric Associates, LLC.


A 1983 graduate of Albany Medical College of Union University, Dr. Goodman completed a medical/psychiatric internship at Baltimore City Hospital and his psychiatric residency at The Johns Hopkins Hospital in 1986.


Dr. Goodman has continued a full time clinical practice focusing on the diagnosis and treatment of mood disorders, adult Attention Deficit/Hyperactivity Disorder, Anxiety Disorders. For almost 30 years, he has been teaching psychiatric residents at The Johns Hopkins Hospital. Dr. Goodman has presented over 600 lectures to primary care physicians, psychiatrists, medical specialists and the general public. His psychiatric commentary has been featured on national (ABC World News, CNN Anderson Cooper 360, ESPN Sports Center) and regional television around the country, PBS and national affiliate stations, national magazines (U.S. News and World Report, Wall Street Journal, New York Times, USA Weekend Magazine, Boston Globe, BusinessWeek) and radio interviews around the country. Dr. Goodman has been an ADHD consultant to Major League Baseball and is now a consultant to the National Football League.


Dr. Goodman has been a Principal Investigator for multi-site Phase II and III drug trials for the treatment of adult Attention Deficit/Hyperactivity Disorder and Major Depression. Dr. Goodman is the lead author on the largest adult ADHD trial published and the lead author on the largest survey assessment of physician clinical practice for adults with ADHD. He has published articles in peer-reviewed journals, authored four book chapters and The Black Book of ADHD. He serves as a prepublication peer reviewer for several national and international psychiatric journals. He continues to treat patients in a full time clinical practice.


Registration Needs updating Register Now
Currency:

USD

Registration Cost
Type
Early Registration

2017-08-10
Late Registration From: 2017-08-11 To: 0--
On site Registration
Psychiatry member
99
149
0
Psychiatry Non Member
149
199
0
NEI Member
649
749
0
NEI Non Member
799
899
0

Group Registrations:

Group registrations not allowed

Accompanying Persons:

Accompanying persons not allowed

Registration Documents:
Letter of invitation:
We don’t provide letter of invitation
Letter of confirmation:
We don’t provide Letter of Confirmation
Proof of professional / educational status:
We don’t need Proof of professional/educational status
Online Abstract Submission:

We don’t accept Online Abstracts

Accommodation
Accommodation:

THE BROADMOOR

1 Lake Avenue

Colorado Springs, CO 80906

(719) 623-5112

www.broadmoor.com


CHEYENNE MOUNTAIN RESORT - OVERFLOW HOTEL

3225 Broadmoor Valley Rd.

Colorado Springs, CO 80906

(719) 538-4000

www.cheyennemountain.com

Accommodation Options and Cost

Hotel Name
Type of charge
Single
Room
Double
Room
Distance from Venue
The BROADMOOR
Date range
184
234
CHEYENNE MOUNTAIN RESORT
Date range
159
179
Scientific Content Up to Date
Submission Info

The NEI Congress Scientific Poster Session is one of the highlights of NEI's Psychopharmacology Congress—researchers, clinicians, and top opinion leaders present cutting-edge research, clinical trial data and clinical cases—nearly 1,000 NEI Congress registrants attend this event.


The annual Scientific Poster Session is an opportunity to share, disseminate, and promote your accomplishments and contributions to the field. The full spectrum of neuroscience and mental health research will be considered for inclusion, including basic science, clinical, and epidemiological. First-time and previously submitted (encore) presentations are welcomed for submission. NEI does not charge a submission fee.


Abstracts of presented posters will be published in CNS Spectrums, an indexed Medicus/MEDLINE, peer-reviewed scholarly journal—one of the top journals in Clinical Neurology and Psychiatry, with an Impact Factor ranking of 3.582!


All Young Investigators are invited to submit a copy of their posters by October 3, 2017 to be entered into the Young Investigators Poster Competition. Submissions will be reviewed by our faculty panel, and the top 3 winning posters will be announced during the Poster Session.


Make useful connections as you network with leaders in the field—submit your poster for presentation at the NEI Congress Scientific Poster Session!


Abstract submission deadline 2017-08-15
Sponsors Exhibitors
General Info

The 2017 NEI Congress is the premier psychopharmacology conference for you to reach 1,300 mental health professionals specializing in psychiatry, psychiatric nursing, primary care, and psychology.


Join us at this year's conference to expand your reach to a new audience. Take advantage of our multiple sponsorship and exhibition opportunities to raise the recognition of your company.

Exhibition Consensus
Exhibition Floor plans
Contact
Organising Agency

Zamanda Garcia , Project Manager , NEI

Phone: 888-535-5600

Email: zgarcia@neiglobal.com

Event map
Revelant Events